249 related articles for article (PubMed ID: 22393002)
1. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.
Chapuis AG; Thompson JA; Margolin KA; Rodmyre R; Lai IP; Dowdy K; Farrar EA; Bhatia S; Sabath DE; Cao J; Li Y; Yee C
Proc Natl Acad Sci U S A; 2012 Mar; 109(12):4592-7. PubMed ID: 22393002
[TBL] [Abstract][Full Text] [Related]
2. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Wang A; Chandran S; Shah SA; Chiu Y; Paria BC; Aghamolla T; Alvarez-Downing MM; Lee CC; Singh S; Li T; Dudley ME; Restifo NP; Rosenberg SA; Kammula US
Sci Transl Med; 2012 Aug; 4(149):149ra120. PubMed ID: 22932225
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
Wallen H; Thompson JA; Reilly JZ; Rodmyre RM; Cao J; Yee C
PLoS One; 2009; 4(3):e4749. PubMed ID: 19270751
[TBL] [Abstract][Full Text] [Related]
4. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
Chapuis AG; Roberts IM; Thompson JA; Margolin KA; Bhatia S; Lee SM; Sloan HL; Lai IP; Farrar EA; Wagener F; Shibuya KC; Cao J; Wolchok JD; Greenberg PD; Yee C
J Clin Oncol; 2016 Nov; 34(31):3787-3795. PubMed ID: 27269940
[TBL] [Abstract][Full Text] [Related]
5. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
6. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.
Butler MO; Friedlander P; Milstein MI; Mooney MM; Metzler G; Murray AP; Tanaka M; Berezovskaya A; Imataki O; Drury L; Brennan L; Flavin M; Neuberg D; Stevenson K; Lawrence D; Hodi FS; Velazquez EF; Jaklitsch MT; Russell SE; Mihm M; Nadler LM; Hirano N
Sci Transl Med; 2011 Apr; 3(80):80ra34. PubMed ID: 21525398
[TBL] [Abstract][Full Text] [Related]
7. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
[TBL] [Abstract][Full Text] [Related]
8. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; Ochsenreither S; Wölfl M; Bar M; Radich JP; Yee C; Greenberg PD
Sci Transl Med; 2013 Feb; 5(174):174ra27. PubMed ID: 23447018
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
Yee C; Thompson JA; Byrd D; Riddell SR; Roche P; Celis E; Greenberg PD
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16168-73. PubMed ID: 12427970
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
[TBL] [Abstract][Full Text] [Related]
11. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.
Powell DJ; Dudley ME; Robbins PF; Rosenberg SA
Blood; 2005 Jan; 105(1):241-50. PubMed ID: 15345595
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
13. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
[TBL] [Abstract][Full Text] [Related]
14. Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.
Wu RC; Liu S; Chacon JA; Wu S; Li Y; Sukhumalchandra P; Murray JL; Molldrem JJ; Hwu P; Pircher H; Lizée G; Radvanyi LG
Clin Cancer Res; 2012 May; 18(9):2465-77. PubMed ID: 22307139
[TBL] [Abstract][Full Text] [Related]
15. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
16. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.
Meidenbauer N; Marienhagen J; Laumer M; Vogl S; Heymann J; Andreesen R; Mackensen A
J Immunol; 2003 Feb; 170(4):2161-9. PubMed ID: 12574389
[TBL] [Abstract][Full Text] [Related]
17. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
18. Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.
Le Gal FA; Widmer VM; Dutoit V; Rubio-Godoy V; Schrenzel J; Walker PR; Romero PJ; Valmori D; Speiser DE; Dietrich PY
J Invest Dermatol; 2007 Mar; 127(3):622-9. PubMed ID: 17039243
[TBL] [Abstract][Full Text] [Related]
19. Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.
Kaka AS; Shaffer DR; Hartmaier R; Leen AM; Lu A; Bear A; Rooney CM; Foster AE
J Immunother; 2009 Sep; 32(7):726-36. PubMed ID: 19561536
[TBL] [Abstract][Full Text] [Related]
20. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]